evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Dinutuximab‐containing immunotherapy vs usual care

Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Dinutuximab‐containing immunotherapy vs usual care

Event‐free survival · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).

1 finding from 1 review

Dinutuximab‐containing immunotherapy vs usual care

Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Dinutuximab‐containing immunotherapy vs usual care

Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy

Efficacy (functional outcome) · stroke and/or TIA

It is very uncertain whether marine‐derived n‐3 fatty acids therapy changes primary outcome: efficacy (functional outcome) compared with no marine‐derived n‐3 fatty acids therapy (very low certainty).

2 findings from 1 review

Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy

Recurrent events (both ischaemic and haemorrhagic stroke) · stroke and/or TIA

Marine‐derived n‐3 fatty acids therapy showed no clear difference in recurrent events (both ischaemic and haemorrhagic stroke) compared with no marine‐derived n‐3 fatty acids therapy (low certainty).

1 finding from 1 review

Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy

Adverse events · stroke and/or TIA

Marine‐derived n‐3 fatty acids therapy showed no clear difference in adverse events compared with no marine‐derived n‐3 fatty acids therapy (low certainty).

2 findings from 1 review